Eindhoven, The Netherlands, 16 May 2022 – STENTiT is pleased to announce that it will be presenting at the EuroPCR in Paris, the World-Leading Course in interventional cardiovascular medicine.
On Friday 20 May, STENTiT will show for the first time its latest pre-clinical data in the session “Innovative approaches to complex peripheral interventions”, scheduled from 08:30 – 10:00 in the Musée d’Orsay Case Corner.
STENTiT is an emerging player in the field of regenerative medical devices, offering a breakthrough solution for cardiovascular interventions by developing first-of-its-kind endovascular implants with regenerative capacity. Using a catheter-based approach, these devices provide the ability to restore arteries without the need for an invasive surgical intervention. The aim is to ultimately restore the affected blood vessel from the inside out to provide a lifelong solution.
As a first target indication, the company wants to improve the treatment of critical limb ischemia. This progressive form of peripheral artery disease affects almost 5 million people in the EU and the US in which the blood flow to the foot is severely being compromised. Unfortunately, current treatment options are ineffective, resulting in amputation within 6 months in 40% of these patients.
With the regenerative stent, blood flow to the foot will be maintained by securing vascular patency using temporary mechanical support and improving long-term efficacy by inducing vascular repair, thereby preventing thousands of amputations each year.
About EuroPCR
As the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), EuroPCR is a patient-oriented Course built by and for the community covering the latest innovations and advances in cardiovascular interventions. Interventional cardiologists, cardiac surgeons, imaging specialists, radiologists, nurses, allied professionals and other practitioners will be joined by researchers, innovators and industry representatives to address interventions for coronary and peripheral vessels, for structural heart disease including valves, for hypertension, heart failure and stroke.
More information is available on the EuroPCR website
About STENTiT
STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These fibrillated resorbable devices, trigger a natural healing response by which affected blood vessels can be rebuild from the inside out.
More information is available on the STENTiT website
For further enquiries, please contact:
STENTiT | Eindhoven, The Netherlands
Dr. Bart Sanders, CEO
T: +31 40 247 2445
E: b.sanders@stentit.com
